The potential future availability of innovative Alzheimer’s disease (AD) treatments will focus decision-makers on real-world evidence needs. This type of evidence can be used for many types of decision making and is used in health technology assessments (HTA) for establishing health and cost outcomes. Uncertainty relating to long term outcomes for patients, caregivers, health systems and society will be an important focus for decision makers and payors. There is a lack of standardization in the collection of real-world data and there is a need to establish a consensus on what the most important data are in the context of AD, such that improvements in data collection efforts can be made and gaps can be filled.
This educational webinar explores some of the key issues relating to long-term evidence needs within the context of HTA in AD and considers what can be done in the short, medium, and long term to address evidence needs.
- Understand the need for long term evidence to support value assessment in Alzheimer’s disease;
- Learn some of the key challenges in generating long-term real world evidence; and
- Understand specific needs and perspectives of different stakeholders.